TIDMRENX
Renalytix AI PLC
04 February 2021
Renalytix AI plc
("RenalytixAI" or the "Company")
American Society of Nephrology and Renalytix to Co-Host Virtual
Capital Markets Day
for Kidney Health
Event Featuring Leading Clinicians, Biotech Innovators and
Federal Health Agencies
to Highlight Innovation and Opportunity in Kidney Health
NEW YORK, Feb. 4, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ:
RNLX), an artificial intelligence-enabled in vitro diagnostics
company, focused on optimizing clinical management of kidney
diseases to drive improved patient outcomes and advance value-based
care, announced today that it will co-host a Capital Markets Day
for Kidney Health with the American Society of Nephrology (ASN) on
Thursday, February 11 from 8:00 a.m. - 12:30 p.m. EST. The virtual
event will bring together a broad group of delegates representing
the kidney community, including leading clinicians, representatives
of U.S. government health agencies, kidney care innovators and
investors focused on life sciences and medical technology, for a
series of presentations and panel discussions on the challenges and
innovations arising from kidney health and the market opportunity
in this area.
The Capital Markets Day for Kidney Health event will feature
keynote addresses by Susan E. Quaggin, MD, FRCP(C), FASN,
President, American Society of Nephrology and Chief, Division of
Nephrology and Hypertension, Director, Feingberg Cardiovascular and
Renal Research Institute, Charles Horace Mayo Professor of Medicine
at Northwestern University; and Steven Coca, DO, MS, Associate
Professor of Medicine Icahn School of Medicine at Mount Sinai, New
York and co-founder of RenalytixAI. RenalytixAI CEO James
McCullough will also participate in a panel discussion on lead IPOs
in kidney disease in 2020.
The full agenda and registration information can be viewed here
: https://www.asn-online.org/KCMD
Kidney diseases affects 850 million individuals worldwide,
including over 37 million Americans, costing the U.S. healthcare
system over $120 billion per year in Medicare spending alone.(1, 2,
3) Despite the significant patient need, awareness and new product
development has lagged behind many other fields, until now. There
is a trend among healthcare companies, medical providers,
organizations, and researchers to assess early-stage prognosis and
end-to-end integrated solutions for kidney disease in an effort to
prevent the economic and health impacts.
"Better management in kidney disease is happening now, and the
roster of speakers today are innovators in their field and at the
cutting edge of transforming the way we understand the progression
of early-to-end-stage kidney disease," said Susan E. Quaggin, MD.
"As we begin to change the consequences of kidney disease for
patients through the use of emerging technologies, we expect to
begin to see better outcomes for patients as well as benefits in
the health system."
"Kidney disease is one of the biggest unmet public health needs
today. New advancements in precision medicine coupled with
significant recent changes in reimbursement and regulatory policies
have made kidney disease one of the most attractive areas for
innovation and investment in the healthcare space," said James
McCullough, CEO of RenalytixAI.
The list of speakers participating in the Capital Markets Day
for Kidney Health includes:
-- Amy P. Abernathy, MD, PhD, US Food and Drug Administration
-- Daniel Arias, Stifel Financial Corp.
-- Randy Baron, Pinnacle Associates
-- Sara Barrington, Verici DX Limited
-- Steven G. Coca, DO, MS, Icahn School of Medicine at Mount Sinai, Co-Founder, RenalytixAI
-- Jennifer Erickson, Former White House Office of Science and
Technology Policy, Obama Administration
-- Tod Ibrahim, American Society of Nephrology
-- Alan S. Kliger, MD, Yale University School of Medicine
-- Leslie Trigg, Outset Medical, Inc.
-- Kevin Longino, National Kidney Foundation
-- Rachel N. Meyer, American Society of Nephrology
-- James McCullough, RenalytixAI
-- Susan E. Quaggin, MD, FASN, American Society of Nephrology, Northwestern University
-- Anne Rohall-Andrade, Living Kidney Donor, Former HHS Office
of Assistant Secretary for Health, Trump Administration
-- Prabir Roy-Chaudhury, MD, PhD, FRCP, University of North
Carolina, Chapel Hill, American Society of Nephrology
-- Jeffrey Shuren, MD, JD, US Food and Drug Administration
-- Boris Vuchic, Crescent Rock Capital
This event is intended for investors only. Media interested in
more information can contact jmoritz@0to5.com .
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year, kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while
waiting for a kidney transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About the American Society of Nephrology
Since 1966, ASN has been leading the fight to prevent, treat,
and cure kidney diseases throughout the world by educating health
professionals and scientists, advancing research and innovation,
communicating new knowledge, and advocating for the highest quality
care for patients. ASN has more than 20,000 members representing
131 countries. For more information, please visit
www.asn-online.org or contact the society at 202-640-4660.
About RenalytixAI
RenalytixAI (LSE: RENX) (NASDAQ: RNLX) is a developer of
artificial intelligence-enabled clinical in vitro diagnostic
solutions for kidney disease, one of the most common and costly
chronic medical conditions globally. The Company's lead product is
KidneyIntelX.com (visit www.kidneyintelx.com ) which is being
designed to help make significant improvements in kidney disease
prognosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery.
For more information, visit www.renalytixai.com
Sources
(1) American Society of Nephrology
(2) Centers for Disease Control and Prevention
(3) United States Renal Data System
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Examples of these forward-looking statements
include statements concerning the ability of technological and
other advancements to curtail costs of CKD and end-stage kidney
disease and improve patient outcomes. Words such as "anticipates,"
"believes," "estimates," "expects," "intends," "plans," "seeks,"
and similar expressions are intended to identify forward-looking
statements. We may not actually achieve the plans and objectives
disclosed in the forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Any
forward-looking statements are based on management's current views
and assumptions and involve risks and uncertainties that could
cause actual results, performance or events to differ materially
from those expressed or implied in such statements. These and other
risks are described more fully in our filings with the Securities
and Exchange Commission (SEC), including the "Risk Factors" section
of our annual report on Form 20-F filed with the SEC on October 28,
2020, and other filings we make with the SEC from time to time. All
information in this press release is as of the date of the release,
and we undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKQBBABKKABK
(END) Dow Jones Newswires
February 04, 2021 02:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Renalytix (LSE:RENX)
Historical Stock Chart
From Jan 2024 to Jan 2025
